dc.contributor.author | Strollo, Rocky | |
dc.contributor.author | Ponchel, Frederique | |
dc.contributor.author | Malmström, V | |
dc.contributor.author | Rizzo, P | |
dc.contributor.author | Bombardieri, M | |
dc.contributor.author | Wenham, CY | |
dc.contributor.author | Landy, R | |
dc.contributor.author | Perret, D | |
dc.contributor.author | Watt, F | |
dc.contributor.author | Corrigall, VM | |
dc.contributor.author | Winyard, Paul G. | |
dc.contributor.author | Pozzilli, P | |
dc.contributor.author | Conaghan, PG | |
dc.contributor.author | Panayi, GS | |
dc.contributor.author | Klareskog, L | |
dc.contributor.author | Emery, Paul | |
dc.contributor.author | Nissim, Ahuva | |
dc.date.accessioned | 2013-11-14T14:14:41Z | |
dc.date.issued | 2013-04-10 | |
dc.description.abstract | Type II collagen (CII) posttranslationally modified by reactive oxygen species (ROS-CII) that are present in the inflamed joint is an autoantigen in rheumatoid arthritis (RA). The aim of this study was to investigate the potential use of anti-ROS-CII autoantibodies as a biomarker of RA. | en_GB |
dc.identifier.citation | Vol. 65, Issue 7, pp. 1702 - 1712 | en_GB |
dc.identifier.doi | 10.1002/art.37964 | |
dc.identifier.uri | http://hdl.handle.net/10871/13950 | |
dc.language.iso | en | en_GB |
dc.publisher | Wiley-Blackwell | en_GB |
dc.relation.url | http://www.ncbi.nlm.nih.gov/pubmed/23575908 | en_GB |
dc.rights.embargoreason | Publisher's policy | en_GB |
dc.title | Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis | en_GB |
dc.type | Article | en_GB |
dc.identifier.issn | 0004-3591 | |
dc.identifier.journal | Arthritis and Rheumatism | en_GB |